MISSISSAUGA, Ontario — December 15, 2025 — Novo Nordisk Canada Inc. announced that Health Canada has granted conditional marketing authorization (Notice of Compliance with Conditions, NOC/c) for Wegovy® (semaglutide injection) as a treatment for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (F2–F3). This decision establishes Wegovy® as the first and only approved pharmacological treatment in Canada for this serious, progressive liver disease and reflects the growing regulatory recognition of GLP-1–based therapies beyond metabolic and cardiovascular indications.
Science Significance
From a scientific perspective, the authorization represents a major advance in liver disease therapeutics, an area historically marked by limited treatment options. MASH is characterized by hepatic fat accumulation, inflammation, and fibrosis that can progress to cirrhosis, hepatocellular carcinoma, and liver failure. Wegovy® (semaglutide 2.4 mg), a once-weekly GLP-1 receptor agonist, demonstrated compelling histological benefits in the Phase 3 ESSENCE trial, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis without worsening liver injury. These dual primary endpoints underscore the therapy’s disease-modifying potential, positioning semaglutide as a scientifically credible option to alter the natural history of MASH rather than merely managing metabolic risk factors.
Regulatory Significance
The decision by Health Canada to grant conditional authorization under the NOC/c pathway highlights the regulator’s assessment that Wegovy® demonstrates acceptable safety, high quality, and promising efficacy, while acknowledging the need for confirmatory long-term clinical outcomes. The authorization was further accelerated under Priority Review, signaling the agency’s recognition of the high unmet medical need in MASH. For cGxP stakeholders, this milestone reflects rigorous evaluation across clinical evidence, biologics manufacturing quality, and pharmacovigilance commitments, with ongoing obligations tied to the completion of Part 2 of the ESSENCE trial, which will assess reduction in liver-related clinical events.
Business Significance
Advertisement
Commercially, the authorization significantly expands Wegovy®’s lifecycle value in Canada, adding a high-burden liver disease indication to its existing approvals in obesity management and cardiovascular risk reduction. With MASH prevalence expected to rise sharply by 2030, Novo Nordisk is positioned to address a growing therapeutic market with substantial long-term demand. The approval strengthens the company’s hepatic and cardiometabolic portfolio strategy, reinforces its leadership in GLP-1 innovation, and supports continued investment in manufacturing scale, supply reliability, and market access infrastructure to meet anticipated uptake.
Patients’ Significance
For patients, the impact is profound. Prior to this decision, no approved pharmacological treatment was available in Canada for MASH, leaving patients reliant on lifestyle modification and management of comorbidities. Wegovy® offers new hope for disease control, particularly for individuals at risk of progression to cirrhosis or liver cancer. Clinical evidence indicating fibrosis stabilization and reversal suggests the potential to delay or prevent severe outcomes, reduce the need for liver transplantation, and improve long-term survival and quality of life. The once-weekly administration also supports treatment adherence in a chronic disease setting.
Policy Significance
At a policy level, the authorization aligns with broader public health priorities focused on chronic disease prevention, early intervention, and reducing downstream healthcare costs. As awareness of MASH remains low despite its prevalence, regulatory recognition of an effective therapy may catalyze earlier diagnosis, guideline updates, and screening initiatives. The decision also reflects Health Canada’s willingness to leverage conditional approval mechanisms to accelerate access to therapies addressing serious, life-threatening conditions, while maintaining post-market evidence requirements to ensure sustained benefit.
Health Canada’s conditional approval of Wegovy® for non-cirrhotic MASH marks a pivotal moment in the evolution of liver disease treatment in Canada. By combining robust Phase 3 evidence, regulatory flexibility, and post-authorization commitments, the decision exemplifies how science-driven innovation and regulatory oversight can converge to address urgent unmet needs. For the cGxP.wire audience, this milestone underscores the expanding role of GLP-1–based biologics, the importance of global regulatory alignment, and the growing emphasis on quality, compliance, and lifecycle management in bringing transformative therapies to patients.
Source: Novo Nordisk Canada Inc. press release
